Back to search results

Thalamus Seizure Detection with a Deep Brain Stimulator System

This study is looking at how well a deep brain stimulator (DBS) system, specifically the Medtronic Percept™ DBS, can detect seizures in the thalamus (a part of the brain). The goal is to see if this system can accurately identify seizures in people with epilepsy that hasn't responded to other treatments. Researchers will compare the DBS system's readings to standard video-EEG monitoring (a test that records brain activity and video) to see how sensitive and specific the DBS detection is. This study is for adults aged 18 and older who already have a Medtronic Percept™ DBS system implanted for epilepsy. Success will be measured by how accurately the DBS system detects seizures over two years.

Study design
This is an interventional study involving 5 participants with drug-resistant epilepsy who already have a Medtronic Percept™ DBS system implanted.
What's involved
Participants will undergo evaluation in an epilepsy monitoring unit, where their antiseizure medications may be adjusted. They will then transition to an outpatient setting for ongoing thalamus recordings.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint for measuring thalamic seizure detection is at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06700356

Thalamus Seizure Detection With a Deep Brain Stimulator System

Recruiting
NAAges 18+InterventionalBasic science
Mayo Clinic
~5 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Phase 1-Validation of thalamus seizure detection with concurrent video EEG monitoringPhase 2-DBS Stimulation with Medtronic Percept DBS device-Out Patient

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Thalamic seizure detection in the epilepsy monitoring unit
Measured over 2 years

Conditions

Epilepsy; Seizure

Explore related trials

Seizure Disorder

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Nicholas Gregg · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Karla Crockett
[email protected]
507-538-4880
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years of age and older.
Implanted with a clinical DBS system for epilepsy with brain recording capabilities (Medtronic Percept™ DBS).
Subject or legally authorized representative is able to understand study procedures and to comply with them for the entire length of the study.

Exclusion

Health status or any clinical conditions (e.g., life expectancy, co-existing disease) that, in the opinion of the site investigator, would pose undue risk to undergo epilepsy monitoring unit evaluation for the purpose of seizure characterization.
Women will verify not pregnant, and if applicable, have urine pregnancy test.
Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
Inability or unwillingness of individual or legal guardian/representative to give written informed consent.

What this trial measures

  • Thalamic seizure detection in the epilepsy monitoring unit2 years

    The sensitivity, specificity, and false alarm rate of thalamus seizure detection will be calculated using recordings from a deep brain stimulation system, assessed relative to concurrent gold-standard video-EEG monitoring collected in the epilepsy monitoring unit, in patients with drug resistant epilepsy.